Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501378 | 0.81 | IKBKE (0.48) | IKBKEJAK2HTR7ATMADORA2A | |
| SCHEMBL1143552 | 0.80 | IKBKB (0.50) | HTR7ADORA2AADORA1 | |
| SCHEMBL29875138 | 0.79 | ADORA2A (0.50) | IKBKEJAK2HTR7ATMADORA2A | |
| SCHEMBL19927651 | 0.79 | ADORA2A (0.50) | IKBKEJAK2HTR7ATMADORA2A | |
| SCHEMBL4005629 | 0.79 | ALDH1A1 (0.53) | ATMALDH1A1IDO1 | |
| SCHEMBL12398398 | 0.76 | IKBKE (0.54) | IKBKEJAK2HTR7ADORA2AADORA1 | |
| SCHEMBL29874866 | 0.76 | IKBKE (0.54) | IKBKEJAK2HTR7ADORA2AADORA1 | |
| SCHEMBL930181 | 0.72 | IKBKE (0.56) | IKBKEJAK2ALDH1A1POLBAPOBEC3G | |
| SCHEMBL14809717 | 0.72 | MAP2K4 (0.55) | IKBKEJAK2ALDH1A1IDO1NPY5R | |
| SCHEMBL15038415 | 0.72 | ADORA2A (0.53) | IKBKEJAK2ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633200-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2614064-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-06 | — | — | US | disclosed |
| WO-2012033735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | IKBKE 437/4885JAK2 2822/4885HTR7 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.